A Phase 3 interventional study of LOU064 in Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals. Completed at 13 sites in Japan. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-04-08.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing remibrutinib in Chronic Urticaria — 2 open to participants now, 6 under way, 5 of them phase 3. remibrutinib · Chronic Urticaria.
Among the 12 studies testing remibrutinib in Chronic Urticaria, this one is the 11th largest by enrollment, is one of 2 that started in 2022, is one of 9 in phase 3, and was the 5th registered.
197 studies on the registry are indexed under Chronic Urticaria; 48 are open to participants now.
Browse Chronic Urticaria studies →2 of the 12 studies testing remibrutinib in Chronic Urticaria are open now, in 9 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Canada, Hong Kong, Japan and 1 more country
Ages 18+
Novartis Pharmaceuticals · Sites in United States, France, Germany and 2 more countries
Ages 18+
By country, each count listing its studies:
remibrutinib: first FDA approval 2025 (RHAPSIDO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 71 is below the median of 80 across 147 interventional studies indexed under Chronic Urticaria.
Median enrollment 347 across the 12 interventional studies. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 1 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
38 studies in Chronic Urticaria by Novartis: 7 open now, 12 under way, 5 of them phase 3. Of 24 finished, 19 (79%) have results posted.
Among the 38 studies in Chronic Urticaria by Novartis, this one is the 20th largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2022, is one of 16 in phase 3, and was the 22nd registered.
Novartis’s Chronic Urticaria studies by the year they started, since 2007.
2 of the studies testing remibrutinib in Chronic Urticaria that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06868212Phase 3Novartis PharmaceuticalsA Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines | 2027-02-22 |
| NCT06865651Novartis PharmaceuticalsStudy of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria | 2027-08-23 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing remibrutinib in Chronic Urticaria, from their registry updates:
Among Novartis’s 38 in Chronic Urticaria:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the safety, tolerability and efficacy of remibrutinib (LOU064) in adult Japanese patients chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment by H1-antihistamine (H1-AH) at locally label approved doses, for a duration of 52 weeks of treatment with remibrutinib and a post-treatment follow-up period of up to 4 weeks.
The study consisted of three periods, the total study duration is up to 60 weeks: screening period of up to 4 weeks, open-label treatment period of 52 weeks (remibrutinib 25 mg b.i.d.), and a treatment free follow-up period of 4 weeks.
It was planned to include approximately 70 patients in the study; 71 patients were enrolled and included in the analyses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of CSU inadequately controlled by second generation H1-AHs at the time of baseline (Day 1) defined as:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients were treated with remibrutinib 25 mg bis in die/twice a day (b.i.d.). LOU064 open-label treatment taken orally for 52 weeks.
Drug: LOU064
Each patient took one film-coated tablet in the morning and one film-coated tablet in the evening (except the morning dose at the PK sampling visits, which were to be taken on site during the visit).
Also known as: remibrutinib
Number of Participants With Treatment Emergent Adverse Events
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. Treatment emergent Adverse Event (TEAEs) in this study are events that started after the first dose of study treatment and until 30 days after the last study treatment, or events present prior to the first dose of treatment which increased in severity based on preferred term within 30 days after the last study treatment.
Time frame: Baseline up to 30 days after last dose of study medication, assessed up to approximately 56 weeks
Mean Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12
Change from Baseline in Weekly Urticaria Activity Score (UAS7) was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The Weekly Urticaria Activity Score (UAS7) is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the weekly UAS7 score is 0 - 42 (highest hives and itch severity).
Time frame: Baseline, Week 12
Number of Participants Who Achieved Disease Activity Control (UAS7 =< 6) at Week 12
The percentage of patients achieving disease activity control (UAS7 =\< 6) at Week 12 was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).
Time frame: Week 12
Number of Participants Who Achieved Complete Absence of Hives and Itch (UAS7 = 0) at Week 12
The proportion of patients achieving complete absence of hives and itch (UAS7 = 0) at Week 12 was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).
Time frame: Week 12
Change From Baseline in Weekly Itch Severity Score (ISS7) at Week 12
The severity of the itch was recorded by the participant twice daily in their electronic Diary, on a scale of 0 (none) to 3 (severe). A weekly score (ISS7) was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 - 21 (highest itch severity).
Time frame: Baseline, Week 12
Change From Baseline in Weekly Hives Severity Score (HSS7) at Week 12
The hives (wheals) severity score, defined by number of hives, was recorded by the participant twice daily in their electronic Diary, on a scale of 0 (none) to 3 (\> 12 hives/12 hours). A weekly score (HSS7) was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 - 21 (highest hives activity).
Time frame: Baseline, Week 12
Number of Participants Who Achieved Early Onset of Disease Activity Control (UAS7 =< 6) at Week 2
The percentage of patients achieving disease activity control (UAS7 =\< 6) at Week 2 was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).
Time frame: Week 2
Number of Participants Who Achieved Dermatology Life Quality Index (DLQI) = 0-1 at Week 12
The Dermatology Life Quality Index (DLQI) is a 10-item (grouped in 6 domains) dermatology-specific quality of life (QoL) measure. Participants are rating their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days. An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease-related QoL). Domain scores are calculated for: Symptoms and Feelings (0-6), Daily Activities (0-6), Leisure (0-6), Work and School (0-3), Personal Relationships (0-6), Treatment (0-3). The overall DLQI score range was split into score bands and validated in terms of their meaning/relevance to patients as follows: 0-1 (No effect on patient's life), 2-5 (Small effect on patient's life), 6-10 (Moderate effect on patient's life), 11-20 (Very large effect on patient's life), 21-30 (Extremely large effect on patient's life).
Time frame: Week 12
Mean Cumulative Number of Weeks With Disease Activity Control (UAS7 =< 6) up to Week 12
Maintaining disease activity control was assessed as cumulative number of weeks with an UAS7 =\< 6 response between baseline and Week 12. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).
Time frame: Up to Week 12
Mean Cumulative Number of Angioedema Occurrence-free Weeks (AAS7 = 0 Response) up to Week 12
Angioedema occurrence was recorded once daily in the evening in the electronic Diary by the participant. Reporting the occurrence of angioedema was used as opening question for the assessment of the Angioedema Activity Score (AAS). The AAS consists of 5 questions with 4 answer options (scored 0-3) for each item, with a minimum score of 0 and a maximum score of 15 per day. The AAS score over 7 days (AAS7) ranges from 0 (no angioedema episodes) to 105 (highest angioedema severity).
Time frame: Up to Week 12
This study was conducted at 13 centers in Japan.
| Milestone | LOU064 25 mg b.i.d. |
|---|---|
| Started | 71 |
| Completed | 68 |
| Not completed | 3 |
| Withdrew: Adverse event | 1 |
| Withdrew: Subject decision | 2 |
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. Treatment emergent Adverse Event (TEAEs) in this study are events that started after the first dose of study treatment and until 30 days after the last study treatment, or events present prior to the first dose of treatment which increased in severity based on preferred term within 30 days after the last study treatment.
| Participants | LOU064 25 mg b.i.d. |
|---|---|
| Subjects with at least one Adverse Event (AE) | 62 |
| Subjects with serious or other significant events - Death | 0 |
| Subjects with serious or other significant events - Non-fatal SAE(s) | 3 |
| Subjects with serious or other significant events - Discontinued study treatment due to any AE(s) | 1 |
Change from Baseline in Weekly Urticaria Activity Score (UAS7) was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The Weekly Urticaria Activity Score (UAS7) is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the weekly UAS7 score is 0 - 42 (highest hives and itch severity).
| Unit on a scale | LOU064 25 mg b.i.d. |
|---|---|
| Mean Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12 | -18.14 ± 10.992 |
The percentage of patients achieving disease activity control (UAS7 =\< 6) at Week 12 was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).
| Participants | LOU064 25 mg b.i.d. |
|---|---|
| Number of Participants Who Achieved Disease Activity Control (UAS7 =< 6) at Week 12 | 30 |
The proportion of patients achieving complete absence of hives and itch (UAS7 = 0) at Week 12 was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).
| Participants | LOU064 25 mg b.i.d. |
|---|---|
| Number of Participants Who Achieved Complete Absence of Hives and Itch (UAS7 = 0) at Week 12 | 15 |
The severity of the itch was recorded by the participant twice daily in their electronic Diary, on a scale of 0 (none) to 3 (severe). A weekly score (ISS7) was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 - 21 (highest itch severity).
| Unit on a scale | LOU064 25 mg b.i.d. |
|---|---|
| Change From Baseline in Weekly Itch Severity Score (ISS7) at Week 12 | -8.01 ± 4.703 |
The hives (wheals) severity score, defined by number of hives, was recorded by the participant twice daily in their electronic Diary, on a scale of 0 (none) to 3 (\> 12 hives/12 hours). A weekly score (HSS7) was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 - 21 (highest hives activity).
| Unit on a scale | LOU064 25 mg b.i.d. |
|---|---|
| Change From Baseline in Weekly Hives Severity Score (HSS7) at Week 12 | -10.12 ± 6.845 |
The percentage of patients achieving disease activity control (UAS7 =\< 6) at Week 2 was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).
| Participants | LOU064 25 mg b.i.d. |
|---|---|
| Number of Participants Who Achieved Early Onset of Disease Activity Control (UAS7 =< 6) at Week 2 | 29 |
The Dermatology Life Quality Index (DLQI) is a 10-item (grouped in 6 domains) dermatology-specific quality of life (QoL) measure. Participants are rating their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days. An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease-related QoL). Domain scores are calculated for: Symptoms and Feelings (0-6), Daily Activities (0-6), Leisure (0-6), Work and School (0-3), Personal Relationships (0-6), Treatment (0-3). The overall DLQI score range was split into score bands and validated in terms of their meaning/relevance to patients as follows: 0-1 (No effect on patient's life), 2-5 (Small effect on patient's life), 6-10 (Moderate effect on patient's life), 11-20 (Very large effect on patient's life), 21-30 (Extremely large effect on patient's life).
| Participants | LOU064 25 mg b.i.d. |
|---|---|
| Number of Participants Who Achieved Dermatology Life Quality Index (DLQI) = 0-1 at Week 12 | 39 |
Maintaining disease activity control was assessed as cumulative number of weeks with an UAS7 =\< 6 response between baseline and Week 12. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).
| Weeks | LOU064 25 mg b.i.d. |
|---|---|
| Mean Cumulative Number of Weeks With Disease Activity Control (UAS7 =< 6) up to Week 12 | 4.6 ± 4.86 |
Angioedema occurrence was recorded once daily in the evening in the electronic Diary by the participant. Reporting the occurrence of angioedema was used as opening question for the assessment of the Angioedema Activity Score (AAS). The AAS consists of 5 questions with 4 answer options (scored 0-3) for each item, with a minimum score of 0 and a maximum score of 15 per day. The AAS score over 7 days (AAS7) ranges from 0 (no angioedema episodes) to 105 (highest angioedema severity).
| Weeks | LOU064 25 mg b.i.d. |
|---|---|
| Mean Cumulative Number of Angioedema Occurrence-free Weeks (AAS7 = 0 Response) up to Week 12 | 10.0 ± 3.63 |
Collected over On-treatment adverse events and deaths were reported from first dose of study medication up to 30 days after last dose of study medication, assessed up to approximately 56 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LOU064 25 mg b.i.d. | 0/71 (0%) | 3/71 (4.2%) | 53/71 (74.6%) |
| Event | LOU064 25 mg b.i.d. |
|---|---|
| Meniere's diseaseEar and labyrinth disorders | 1/71 |
| Epiretinal membraneEye disorders | 1/71 |
| Rhegmatogenous retinal detachmentEye disorders | 1/71 |
| Event | LOU064 25 mg b.i.d. |
|---|---|
| COVID-19Infections and infestations | 14/71 |
| HeadacheNervous system disorders | 9/71 |
| NasopharyngitisInfections and infestations | 7/71 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 7/71 |
| DiarrhoeaGastrointestinal disorders | 6/71 |
| EczemaSkin and subcutaneous tissue disorders | 6/71 |
| TonsillitisInfections and infestations | 5/71 |
| AcneSkin and subcutaneous tissue disorders | 5/71 |
| PyrexiaGeneral disorders | 4/71 |
| CystitisInfections and infestations | 4/71 |
| Age, Continuous(Years) | LOU064 25 mg b.i.d. |
|---|---|
| Mean | 43.5 ± 12.52 |
| Age, Customized(Participants) | LOU064 25 mg b.i.d. |
|---|---|
| >= 18 and < 65 years | 66 |
| >= 65 and < 85 years | 5 |
| Sex: Female, Male(Participants) | LOU064 25 mg b.i.d. |
|---|---|
| Female | 54 |
| Male | 17 |
| Race/Ethnicity, Customized(Participants) | LOU064 25 mg b.i.d. |
|---|---|
| Asian | 71 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jan 2022 to primary completion in Dec 2023, 22 months.
Results were first posted in Nov 2024, 11 months after primary completion.
Of 27 industry-sponsored phase 3 interventional studies under Chronic Urticaria, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 31. This study's 22 months is close to that.
Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 19 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remibrutinib